



THIS IS WHY I **LUMAKRAS®**

LUMAKRAS® is not intended for use in children.

THE FIRST ONCE-DAILY ORAL TREATMENT¹

For people living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor is KRAS G12C positive, and who have received at least one prior treatment.²

Not Chemotherapy¹

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC):

- that has spread to other parts of the body or cannot be removed by surgery, **and**
- whose tumor has an abnormal KRAS G12C gene, **and**
- who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
 - have liver problems
 - have lung or breathing problems other than lung cancer
 - are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
 - are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.

Please see Important Safety Information throughout and full Important Safety Information on page 14. Click here for full Prescribing Information and Patient Information.



WHAT IS KRAS?



KRAS is a protein that we all have in our body. Proteins are required for the structure and function of the body's cells, tissues, and organs.³



The KRAS protein works like an on/off switch, relaying messages that tell cells when to grow and when to stop growing.⁴

WHAT IS KRAS G12C?



KRAS G12C is a mutation of the KRAS protein. Sometimes a protein can become mutated (altered) and function abnormally.⁴



KRAS G12C causes the on/off switch to get stuck in the “on” position, leading to continuous and uncontrollable cell growth that can form tumors.⁵

KRAS G12C IS FOUND IN

1 IN 8

NSCLC PATIENTS⁶

Important Safety Information (Continued)

What should I tell my healthcare provider before taking LUMAKRAS®?

- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H₂ blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

Please see Important Safety Information throughout and full Important Safety Information on page 14. Click here for full Prescribing Information and Patient Information.

LUMAKRAS®
(sotorasib) 120 mg tablets

HOW DO I KNOW IF I HAVE KRAS G12C?

The only way to know if you have KRAS G12C is by asking your doctor for a biomarker test.⁷ Biomarkers are molecules inside your body that can tell your doctor what kind of NSCLC you may have.⁸



One of the most common NSCLC biomarkers is KRAS G12C. 1 in 8 patients with NSCLC have KRAS G12C.⁶



If you have the KRAS G12C biomarker, it could mean there's a targeted treatment option specially designed for your type of lung cancer.²

HOW WILL MY DOCTOR TEST FOR KRAS G12C?

- Your doctor can test you for the KRAS G12C biomarker by using a biopsy¹
- A biopsy can be done by using either a tissue from the tumor (tissue biopsy) or a blood test (liquid biopsy)¹
- Your doctor will determine which test is right for you¹



Ask your doctor if you've received a biomarker test. LUMAKRAS® may be an option if you tested positive for KRAS G12C.²

Important Safety Information (Continued)

LUMAKRAS® may cause serious side effects, including:

- Liver problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or "tea-colored" urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).

Please see **Important Safety Information** throughout and full **Important Safety Information** on page 14. Click here for full **Prescribing Information** and **Patient Information**.





LUMAKRAS® is not intended for use in children.

HOW LUMAKRAS® WORKS



- LUMAKRAS® is specifically designed for tumors with the KRAS G12C mutation²
- In tumors with this KRAS mutation, the protein remains mostly in an “on” position, and cells are continuously forced to grow⁵
- LUMAKRAS® targets the mutated KRAS protein and locks it in the “off” position. This may prevent tumor cell growth¹



If your cancer is KRAS G12C positive and has been treated with a prior therapy, such as chemotherapy or immunotherapy, ask your doctor if LUMAKRAS® may be able to help.¹

Important Safety Information (Continued)

LUMAKRAS® may cause serious side effects, including:

- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

Please see Important Safety Information throughout and full [Important Safety Information](#) on page 14. Click here for full [Prescribing Information](#) and [Patient Information](#).

LUMAKRAS®
(sotorasib) 120 mg tablets

HOW TO TAKE LUMAKRAS®



Take LUMAKRAS® once daily by mouth with or without food.²



The recommended dose of LUMAKRAS® is 960 mg (eight 120 mg tablets) taken once daily.^{1,2}

- **Take LUMAKRAS® exactly as your healthcare provider tells you to take it.** Do not change your dose or stop taking LUMAKRAS® unless your healthcare provider tells you to
- **Take LUMAKRAS® 1 time each day,** at about the same time each day



Swallow LUMAKRAS® tablets whole. Do not chew, crush, or split tablets. If you cannot swallow LUMAKRAS® tablets whole²:

- **Place your daily dose of LUMAKRAS®** in a glass of 4 ounces (120 mL) of non-carbonated room temperature water without crushing the tablets. Do not use any other liquids
- **Stir** until the tablets are in small pieces (the tablets will not completely dissolve). The color of the mixture may be pale yellow to bright yellow
- **Drink the LUMAKRAS®** and water mixture right away or within 2 hours of preparing. Do not chew pieces of the tablet
- **Rinse the glass** with an additional 4 ounces (120 mL) of water and drink to make sure that you have taken the full dose of LUMAKRAS®
- **If you do not drink** the mixture right away, stir the mixture again before drinking

Please see **Important Safety Information** throughout and full **Important Safety Information** on page 14. Click here for full **Prescribing Information** and **Patient Information**.

LUMAKRAS®
(sotorasib) 120 mg tablets

WHAT SHOULD I DO IF...

I forget or am unable to take LUMAKRAS® at my usual time?

If you miss a dose of LUMAKRAS®, take the dose as soon as you remember. If it has been more than 6 hours, do not take the dose. Take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose.²

I vomited shortly after taking LUMAKRAS®?

If you vomit after taking a dose of LUMAKRAS®, do not take an extra dose. Take your next dose at your regularly scheduled time the next day.²

I take an antacid?

If you take an antacid medicine such as Tums®, take LUMAKRAS® either 4 hours before or 10 hours after the antacid. Speak to your healthcare provider if you are on PPIs or H₂ blockers.²

I'm prescribed other medications?

Before taking LUMAKRAS®, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.²

Important Safety Information (Continued)

The most common side effects

- The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
- These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

Please see Important Safety Information throughout and full [Important Safety Information](#) on page 14. Click here for full [Prescribing Information](#) and [Patient Information](#).





WHAT ARE THE SERIOUS SIDE EFFECTS OF LUMAKRAS®?

If you experience any of these symptoms while taking LUMAKRAS®, you should call your healthcare provider right away.

LUMAKRAS® may cause serious side effects, including²:

- **Liver problems:** LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function.
 - Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen)
- **Lung or breathing problems:** LUMAKRAS® can cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever

Please see Important Safety Information throughout and full [Important Safety Information](#) on page 14. Click here for full [Prescribing Information](#) and [Patient Information](#).

LUMAKRAS®
(sotorasib) 120 mg tablets

WHAT ARE THE POSSIBLE COMMON SIDE EFFECTS OF LUMAKRAS®?

When taking any medication, it's important to be aware of any side effects that you may experience.

Talk to your healthcare provider immediately if you notice any side effects so they can make the appropriate decision about further treatment.² Read below for a list of tips for the most common side effects.

Diarrhea^{2,9}

- Drink plenty of water and other clear liquids to keep yourself hydrated
- Avoid dairy products, spicy foods, alcohol, and caffeine

Muscle or bone pain^{2,10}

- Write down where the pain began, how long it lasts, what makes it feel better, what makes it feel worse, and how it affects your day-to-day life
- Talking to your healthcare provider about the pain will help them determine an appropriate management plan

Nausea^{2,11}

- Eat smaller, more frequent meals
- Don't eat foods that are fried, greasy, spicy, or sweet
- Drink clear liquids and ice-cold beverages

Tiredness^{2,12}

- Space out errands and tasks throughout the day to save energy
- Ask friends and family for help
- Try doing light physical activities that you enjoy

Liver Problems²

Please refer to page 7 to see signs and symptoms of liver problems. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function.

Cough^{2,13}

- Note how often and when you cough
- Tracking your cough can help your healthcare provider determine an appropriate treatment option

Changes in liver function tests and changes in certain other blood tests²

Make sure to ask your healthcare provider about the results of your liver function and other routine blood tests.

These are not all the possible side effects of LUMAKRAS. Call your doctor for medical advice about side effects.

Please see Important Safety Information throughout and full Important Safety Information on page 14. Click here for full Prescribing Information and Patient Information.





SUPPORT DESIGNED AROUND YOU

AMGEN NURSE NAVIGATORS*

Your single point of contact who can help you find the resources[†] that are most important to you. We're here to help you with the following:

- Understand how to get LUMAKRAS®
- Answer questions about paying for LUMAKRAS®
- Help you understand your coverage
- Answer your medication questions
- Connect you to support services

[LEARN MORE](#)

*Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan, and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

[†]Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

**Want to chat? 1-888-4ASSIST (1-888-427-7478)
Monday to Friday, 9:00 AM to 8:00 PM EST**



**Connect with us
www.amgenassist360.com/patient**

Please see Important Safety Information throughout and full Important Safety Information on page 14. Click here for full Prescribing Information and Patient Information.



WHAT ARE MY FINANCIAL SUPPORT OPTIONS?

Commercial Insurance

The Amgen FIRST STEP™ Program can help eligible, commercially-insured patients meet their deductible, co-insurance, or co-payment.*

- \$0 out-of-pocket for first dose
- As little as \$5 out-of-pocket for subsequent doses
- No income eligibility requirement



The Amgen FIRST STEP™ Program Prepaid MasterCard® is issued by Comerica Bank pursuant to license by MasterCard International Incorporated. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. This card can be used only to cover co-payment for eligible prescriptions covered under the program at participating merchant locations where Debit MasterCard is accepted.

*Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Government Insurance (like Medicare)

Amgen Assist 360™ can refer you to independent nonprofit patient assistance programs that may be able to help you afford your LUMAKRAS® co-pay costs.[†]

[†]Program eligibility is based on the nonprofit's criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Uninsured Or Under-insured

AMGEN® Safety Net Foundation

Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost.

[LEARN MORE](#)

Please see Important Safety Information throughout and full [Important Safety Information](#) on page 14. Click here for full [Prescribing Information](#) and [Patient Information](#).

LUMAKRAS®
(sotorasib) 120 mg tablets

WHERE CAN I GET LUMAKRAS®?



There are multiple ways to receive your LUMAKRAS® treatment. Talk to your healthcare provider about options for you.

LUMAKRAS® may be available through a specialty pharmacy. Your healthcare provider can help you find a specialty pharmacy that works with your insurance.

Working with a specialty pharmacy.

Once your insurance coverage has been verified, the specialty pharmacy will contact you to set up delivery of your prescription.

Specialty pharmacy providers may be able to help you with the following:



Fill your prescription
and coordinate home delivery



Help you navigate
your insurance coverage



Connect you
to additional support services



Answer questions
about paying for your treatment

Please see **Important Safety Information** throughout and full **Important Safety Information** on page 14. Click here for full **Prescribing Information** and **Patient Information**.

LUMAKRAS®
(sotorasib) 120 mg tablets

YOU ARE NOT ALONE

The KRAS G12C community is here for you. There are many lung cancer organizations and patient communities that can provide you with useful information, and offer you and your caregiver much needed support. We've included a few examples of independent, non-profit organizations that may be able to help patients with NSCLC.



844-360-5864
www.lungevity.org



800-298-2436
www.go2foundation.org



888-793-9355
www.cancersupportcommunity.org



980-339-5225
www.kraskickers.org



**Connect with patient communities
to help stay informed and receive support.**

The above are examples of independent, non-profit organizations that may provide useful information and resources. Amgen has no control over these programs and provides information as a courtesy only.

Please see **Important Safety Information** throughout and full **Important Safety Information** on page 14. Click here for full **Prescribing Information** and **Patient Information**.



NOTES

You can use this space to write down the questions you'd like to discuss with your doctor, as well as other important information.

References: **1.** LUMAKRAS® (sotorasib) Prescribing Information. Thousand Oaks, CA: Amgen 2021. **2.** LUMAKRAS® (sotorasib) Patient Information. Thousand Oaks, CA: Amgen 2021. **3.** NCI Dictionary of Cancer Terms. NIH National Cancer Institute website. <https://www.cancer.gov/publications/dictionaries/cancer-terms>. Accessed December 16, 2020. **4.** Ryan MB, Corcoran RB. *Nat Rev Clin Oncol.* 2018. Vol.15. **5.** Hong DS, Fakih MG, Strickler JH, et. al. *N Engl J Med.* 2020. **6.** Data on file, Amgen; [Analysis of AACR Genie v8]. **7.** Kalemkerian GP, Narula N, Kennedy EB, et al. *J Clin Oncol.* Vol. 36. 2018. **8.** Pakkala S, Ramalingam S. *JCI Insight.* 2018. **9.** American Cancer Society. Cancer.org. <https://www.cancer.org/treatment/treatments-andsideeffects/physical-side-effects/stool-or-urine- changes/diarrhea.html>. February 1, 2020. Accessed December 17, 2020. **10.** American Cancer Society. Cancer.org. <https://www.cancer.org/treatment/treatments-and-sideeffects/physical-side-effects/pain/pain.html>. January 3, 2019. Accessed May 17, 2021. **11.** American Cancer Society. Cancer.org. <https://www.cancer.org/treatment/treatments-and-sideeffects/physical-side-effects/nausea-andvomiting/nausea-and-vomiting.html>. February 1, 2020. Accessed December 17, 2020. **12.** American Cancer Society. Cancer.org. <https://www.cancer.org/treatment/treatments-and-sideeffects/physical-side-effects/fatigue/managing-cancer-related-fatigue.html>. February 1, 2020. Accessed December 17, 2020. **13.** Doctor-Approved Patient Information from ASCO. Cancer.net. <https://www.cancer.net/coping-with-cancer/physical-emotional-and-socialeffects-cancer/managing-physical-side-effects/cough>. February 2, 2021. Accessed May 5, 2021.

Please see Important Safety Information throughout and full Important Safety Information on page 14. Click here for full Prescribing Information and Patient Information.



Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

- Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
 - have liver problems
 - have lung or breathing problems other than lung cancer
 - are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
 - are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
- Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H₂ blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

- Liver problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
- Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough or fever.
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

- The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
- These are not all the possible side effects of LUMAKRAS®.
Call your doctor for medical advice about side effects.

Please see LUMAKRAS® [Patient Information](#).



Distributed by: Amgen Inc.

© 2022 Amgen Inc. All rights reserved. Thousand Oaks.

For more information, go to www.LUMAKRAS.com
or call 1-800-77-AMGEN (1-800-772-6436).

05/2022 USA-510-81112

